» Articles » PMID: 20031688

Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting

Overview
Date 2009 Dec 25
PMID 20031688
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vitronectin is a multifunctional protein with a multiple binding domain that interacts with a variety of plasma and cell proteins. Vitronectin binds multiple ligands, including the soluble vitronectin receptor. Abciximab binds equally well to soluble vitronectin receptor and glycoprotein IIb/IIIa, because both share the beta(3) subunit. We tested whether vitronectin concentrations correlate with adverse outcomes in acute coronary syndrome patients.

Methods And Results: Baseline serum samples (n=233) from a randomized, placebo-controlled trial of abciximab plus stenting (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting EPISTENT) were retrospectively analyzed. We stratified vitronectin concentrations into the 3 lower quartiles (n=178; <49.7 microg/mL) versus the fourth upper quartile (n=55; >or=49.7 microg/mL). The end point was a major adverse cardiovascular event defined as death, myocardial infarction or urgent revascularization at 30 days and 6 months. A higher proportion of patients with baseline vitronectin >or=49.7 microg/mL had major adverse cardiovascular event than patients with baseline vitronectin <49.7 microg/mL at 30 days (18.2% versus 5.6%; P=0.01) and 6 months (20.0% versus 6.2%; P=0.006). When baseline variables not predictive of major adverse cardiovascular event (eg, troponin positive, history of congestive heart failure, diabetes, history of hypertension, smoking status) were excluded from the multivariate model, only baseline vitronectin >or=49.7 microg/mL (at 30 days: OR, 3.23; 95% CI, 1.23, 8.49; at 6 months: OR, 3.36; 95% CI, 1.33, 8.52) and history of myocardial infarction (at 30 days: OR, 5.02; 95% CI, 1.41, 17.9; at 6 months: OR, 3.99; 95% CI, 1.28, 12.43) remained. No interaction occurred between abciximab and vitronectin.

Conclusions: Our findings indicate that vitronectin may be an independent predictor of adverse cardiovascular outcomes following acute stenting.

Citing Articles

Female-specific neuroprotection after ischemic stroke by vitronectin-focal adhesion kinase inhibition.

Jia C, Lovins C, Malone H, Keasey M, Hagg T J Cereb Blood Flow Metab. 2022; 42(10):1961-1974.

PMID: 35702047 PMC: 9536130. DOI: 10.1177/0271678X221107871.


Liver vitronectin release into the bloodstream increases due to reduced vagal muscarinic signaling after cerebral stroke in female mice.

Keasey M, Lovins C, Jia C, Hagg T Physiol Rep. 2022; 10(9):e15301.

PMID: 35531929 PMC: 9082388. DOI: 10.14814/phy2.15301.


The Role of Matrix Proteins in Cardiac Pathology.

Trinh K, Julovi S, Rogers N Int J Mol Sci. 2022; 23(3).

PMID: 35163259 PMC: 8836004. DOI: 10.3390/ijms23031338.


Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia.

Campeau A, Mills R, Stevens T, Rossitto L, Meehan M, Dorrestein P Mol Psychiatry. 2021; 27(2):1217-1225.

PMID: 34741130 PMC: 9054664. DOI: 10.1038/s41380-021-01339-z.


Blood Vitronectin Induces Detrimental Brain Interleukin-6 and Correlates With Outcomes After Stroke Only in Female Mice.

Jia C, Malone H, Keasey M, Lovins C, Elam J, Hagg T Stroke. 2020; 51(5):1587-1595.

PMID: 32312218 PMC: 7249257. DOI: 10.1161/STROKEAHA.120.029036.